Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial

Cancer

Volumn 104, Issue 8, 2005, Pages 1661-1667

  Blaes, Anne H ^a   Peterson, Bruce A ^b   Bartlett, Nancy ^c   Dunn, David L ^a   Morrison, Vicki A ^b,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Extranodal disease; Posttransplant lymphoproliferative disorders; Rituximab; Solid organ transplantation

Indexed keywords

AZATHIOPRINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PARACETAMOL; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 26444541784     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21391     Document Type: Article

References (40)

1. Swinnen L, Mullen G, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333-3340.
2. Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of PTLD. J Nephrol. 1997;10:136-145.
3. Swinnen LJ. Diagnosis and treatment of transplant related lymphoma. Ann Oncol. 2000;ll(Suppl. 1):45-48.
4. Ho M. Risk factors and the pathogenesis of post-transplant lymphoproliferative disorder. Transplant Proc. 1995;27(5 Suppl.):38-40.
5. Fisher A, Blanche S, Le Bidois, et al. Anti B-cell monoclonal antibody in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451-1456.
6. Benkerrou M, Jais JP, Leblond V, et al. Anti B-cell monoclonal antibody treatment of severe post-transplant B-cell lymphoproliferative disorder: prognosis factors and long-term outcome. Blood. 1998;92:3137-3147.
7. Morrison V, Dunn D, Manivel C, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med. 1994;97:14-24.
8. Starzel TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1984;1:583-587.
9. Stieber AO, Boillot O, Starzel TE. The surgical implications of post-transplant lymphoproliferative disorders. Transplant Proc. 1991;23:1477-1479.
10. Lien Y-H, Schroter GPJ, Weil III R, et al. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant patient with acute pancreatitis. Transplantation. 1991;52:739-742.
11. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus and induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting [review]. Transplantation. 1999;68:1517-1525.
12. Senderowicz A, Vitetta E, Headlee D, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med. 1997;126:882-885.
13. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134:445-450.
14. Yedibela S, Reck T, Niedobitek G, et al. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int. 2003;16:197-201.
15. Verschuuren E, Stevens S, van Imhoff G, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73:100-104.
16. Oertel S, Anagnostopoulos I, Bechstein W, et al. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation. Transplantation. 2000;69:430-432.
17. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003;17:417-422.
18. Pham P, Wilkinson A, Gritsch P, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. Transplant Proc. 2002;34:1178-1181.
19. Berney T, Delis S, Kato T, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation. 2002;74:1000-1006.
20. Cook R, Connors J, Gascoyne R, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet. 1999;354:1698-1699.
21. ZiIz N, Olson L, McGregor C. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant. 2001;20:770-772.
22. Hanto DW, Frizzera F, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982;306:913-918.
23. Hanto DW, Sakamoto K, Purtilo DT, et al. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders. Surgery. 1981;90:204-213.
24. Bartlett NL, Petroni G, Parker B, et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer. 2001;92:207-217.
25. Dummer JS, Bound LM, Singh G, et al. Epstein-Barr virus-induced lymphoma in a cardiac transplant patient. Am J Med. 1984;77:179-184.
26. Shapiro RS, Gross T, Haake R, et al. Epstein-Barr virus (EBV) associated B cell lymphoproliferative disorders (BLPD) following bone marrow transplantation (BMT) [abstract]. Blood. 1992;80:138a.
27. Starzl TE. Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg. 1968;168:416-435.
28. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc. 1969;1:106-112.
29. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. 1981;41:4253-4261.
30. Ghobrial I, Habermann T, Maurer M, et al. Proposed prognostic model for survival in solid organ transplant recipients with post transplant lymphoproliferative disorders (PTLD) [abstract]. Blood. 2003;102:329a.
31. Jones SE, Grozea PN, Miller TP, et al. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol. 1985;3:1318-1324.
32. Choquet S, Leblond V, Jager U, et al. Efficacy of CHOP regimen as first line therapy in posttransplantation lymphoproliferative disorders (PTLD). A retrospective study on 25 cases [abstract]. Blood. 2003;102:496.
33. Swinnen L, LeBlanc M, Kasamon Y, et al. Phase II study of sequential reduction in immunosuppression, Interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder [abstract]. Blood. 2003;102:403a.
34. Shammo J, Parameswaran V, Adler S, et al. CHOP chemotherapy in combination with Rituxan for the management of post-transplant lymphoproliferative disorder [abstract]. Blood. 2003;102:2896.
35. Sampson R, Horsfield C, Mikhaeel G, et al. Posttransplant lymphoproliferatlve disorder: a single centre clinicopathological study of 34 cases complicating solid organ renal transplants [abstract]. Blood. 2003;102:310b.
36. Oertel S, Zeidler K, Papp-Vary M, et al. Monotherapy with the anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disease. Results of a multicentre phase II study [abstract]. Blood. 2003;102:413a.
37. Choquet S, LeBlond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post transplantation lymphoproliferative disorders: final results of a multicenter, open label, phase II trial [abstract]. Blood. 2003;102:277a-278a.
38. Milpied N, Vasseur V, Parquet N, et al. Humanized anti-CD 20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11(Suppl.1):113-116.
39. Gamier JL, Stevenson F, Blanc-Brunat N, et al. Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res. 2002;159:113-122.
40. Horowitz SM, Tsai D, Twist C, et al. Rituximab is effective therapy for post-transplant lymphoproliferative disorders not responding to reduction in immunosuppression: a prospective trial in adults and children [abstract]. Proc Annu Meet Am Assoc Cancer Res. 2001;20:284a.